Search

Your search keyword '"Popovici-Muller, Janeta"' showing total 38 results

Search Constraints

Start Over You searched for: Author "Popovici-Muller, Janeta" Remove constraint Author: "Popovici-Muller, Janeta"
38 results on '"Popovici-Muller, Janeta"'

Search Results

2. AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency

3. A chemical biology screen identifies a vulnerability of neuroendocrine cancer cells to SQLE inhibition

7. An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells

8. Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation

9. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer

10. Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies

11. Method for quantitative protein-ligand affinity measurements in compound mixtures

12. Correction: Corrigendum: Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer

13. Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma

14. Fused bi-heteroaryl substituted hydantoin compounds as TACE inhibitors

15. Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers

16. Abstract B126: AG-881, a brain penetrant, potent, pan-mutant IDH (mIDH) inhibitor for use in mIDH solid and hematologic malignancies

19. Erratum: Corrigendum: Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer

20. 2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors

21. Structure and activity relationships of tartrate-based TACE inhibitors

22. Discovery and SAR of hydantoin TACE inhibitors

23. The discovery of novel tartrate-based TNF-α converting enzyme (TACE) inhibitors

24. Novel TNF-α converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases

25. AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo

26. Abstract 1194: IDH1 mutant inhibitor induces cellular differentiation and offers a combination benefit with Ara-C in a primary human Idh1 mutant AML xenograft model

30. Small Molecule Activation Of Pyruvate Kinase Normalizes Metabolic Activity In Red Cells From Patients With Pyruvate Kinase Deficiency-Associated Hemolytic Anemia

31. IDH1 Mutant Inhibitor Induces Cellular Differentiation and Offers a Combination Benefit With Ara-C In a Primary Human Idh1 Mutant AML Xenograft Model

32. Mutation Selective IDH Inhibitors Mediate Histone and DNA Methylation Changes

33. Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo

34. Abstract LB-164: IDH mutations and tumorgenicity

35. Abstract 2785: Modulating the interaction between cdk2 and cyclin A: Screening, synthesis and characterization of a quinoline-based inhibitor

37. Aminothiazole inhibitors of HCV RNA polymerase

38. Corrigendum: Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer.

Catalog

Books, media, physical & digital resources